Foley attorneys filed two amicus briefs with the Federal Circuit in the
AMP et al. v. USPTO et al. (ACLU v. Myriad), a much discussed case relating to gene patents. Foley attorneys submitted one brief on behalf of
Rosetta Genomics and George Mason University. Different Foley attorneys also filed a different brief on behalf of
Alnylam Pharmaceuticals. Both briefs conclude that isolated DNA composition claims are patent eligible under current law, and should continue to meet the threshold of 35 U.S.C. § 101 when applying scientific facts to the law.